The IL-6 antibody (siltuximab, CNTO 328) and IL-6 receptor antibody (tocilizumab) belong to a class of therapeutics clinically approved for patients with malignant cancers, including prostate, ovarian, and lung cancers [29–32]. This evidence concerns the gene IL6 and lung carcinoma.